| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6063621 | Journal of Allergy and Clinical Immunology | 2016 | 8 Pages |
Abstract
Benefits of omalizumab treatment were evident early (before week 4) in some patients and persisted to week 24. Use of 300Â mg of omalizumab demonstrated best results in controlling CIU/CSU symptoms.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Allen MD, Marta MD, PhD, Jonathan A. MD, Evgeniya MS, PhD, Benjamin MS, Karina MS, Karin MD, PhD, Theodore A. MD, MBA, Sam PhD, James L. PhD, MPH,